Development of a natural therapeutic treatment for late-stage lung cancer patients

Project Information

CB24

Grant agreement ID: 190166095

DOI 10.3030/190166095

EC signature date 9 October 2023

Start date 1 October 2023

End date 30 September 2025

Funded under

• The European Innovation Council (EIC)

Total cost € 3 855 337,50

EU contribution € 2 499 999,00

Coordinated by

CELTIC BIOTECH LTD
Ireland

Project description

Confronting non-small cell lung cancer challenges with innovative therapies

Non-small cell lung cancer (NSCLC) destroys lives worldwide, with traditional treatments targeting life extension and overall survival measured in months. Surgery, chemotherapy, radiotherapy, and even newer gene therapies and immunotherapies present challenges in terms of side effects and patient response, especially for those in advanced stages. With this in mind, Celtic Biotech in Ireland developed CB-24, a naturally derived receptor binding protein. Delivered as a user-friendly at-home monotherapy using infusion pumps, it boasts unprecedented efficacy, safety, and minimal side effects, challenging the status quo of NSCLC treatment. The EIC-funded CB24 project aims to validate its success, propelling it through Phase I clinical trials and towards regulatory approval as a game-changing cancer therapeutic.

Objective

Celtic Biotech Ireland has developed CB24(Crotoxin). A naturally derived receptor binding protein, delivered as monotherapy at home using infusion pumps, is hailed as a life changing treatment of Non-Small Cell Lung Cancer (NSCLC). Delivered intravenously, CB24 induces predictable and consistent apoptosis (cell death) and autophagy (degradation) in human lung carcinoma cells. CB24 outclass the competitive NSCLC treatment solutions (surgery, chemotherapy, and radiotherapy) through its efficacy, safety, minimal side-effects, easy to use home based treatment and suitability for all patients including those at stage 3 & 4.

Celtic have already proven the efficacy of CB24 through pre-clinical and FIH clinical trials.

Through the proposed 24months EIC project, the company aims to undertake Phase I Part 3 clinical trials involving 24 patients with the ultimate goal of garnering the regulatory approvals (EMA, FDA) to market the drug as a verified cancer therapeutic.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.

• medical and health sciences › clinical medicine › oncology › lung cancer

You need to log in or register to use this function

Keywords

• Snake Venom
• intravenously administered drug
• Crotoxin
• late stage cancer treatment
• cancer treatment
• Non-small cell lung cancer (NSCLC)

Programme(s)

• HORIZON.3.1 - The European Innovation Council (EIC) Main Programme

Topic(s)

• HORIZON-EIC-2023-ACCELERATOROPEN-01 - EIC Accelerator Open 2023

Call for proposal

HORIZON-EIC-2023-ACCELERATOR-01

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Coordinator

CELTIC BIOTECH LTD

• Net EU contribution: € 2 499 999,00
• Address: 38/39 FITZWILLIAM SQ. WEST ; D02 NX53 DUBLIN ; Ireland
• SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes:
  Activity type
  Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: € 3 855 337,50